Desenvolvimento de Produto Farmacêutico
Resumo
A inovação tecnológica é importante no desenvolvimento de produto farmacêutico com impacto no crescimento dos negócios. Com toda a base de pesquisas elaborada durante a fase de preformulação é possível estabelecer uma estratégia de desenvolvimento do produto de forma que sejam elaborados processos de fabricação robustos, com desenhos de testes específicos, com suas respectivas especificações e faixas de trabalho, para cada finalidade almejada durante a etapa de desenvolvimento e/ou para um componente específico da formulação proposta. O presente trabalho indica os processos que envolvem a transferência de tecnologia no desenvolvimento de produto farmacêutico para formulações no estado sólido.
Referências
1. International Conference on Harmonisation of TechnicalRequirements for Registration of Pharmaceuticals for Human Use,ICH Harmonised Tripartite Guideline Pharmaceutical DevelopmentICH Q8 (R2) 2009.
2. International Conference on Harmonisation of TechnicalRequirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline Quality Risk Management ICH Q9 2005.
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline Pharmaceutical Quality System ICH Q10 2008.
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Technical and regulatory considerations for pharmaceutical product lifecycle management Q12, Nov. 2019.
5. Brasil. Resolução RDC n.º 301, de 21 de Agosto de 2019. Diretrizes Gerais de Boas Práticas de Fabricação de Medicamentos. Diário Oficial da União, Ed. 162, Seção 1.p.64
6. Brasil Resolução RDC n.º 359, de 27 de Março de 2020. Dossiê de Insumo Farmacêutico Ativo (DIFA) e a Carta de Adequação de Dossiê de Insumo Farmacêutico Ativo (CADIFA). Diário Oficial da União, Ed. 63, Seção 1.p.87
7. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Stability Testing of New Drugs Substances and Products Q1A (R2), Feb. 2003.
8. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances Q6A 1999.
9. RODRIGUES, P. H. A., COSTA, R. D. F., KISS, C., A evolução recente da indústria farmacêutica brasileira no s limites da subordinação econômica, Physis: Revista de Saúde Coletiva, Rio de Janeiro, v. 28(1), e280104, 2018
10. LU J., ROMANÍ S. Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs) Curr. Med. Chem. 2009; 16:884–905.
11. BHARATE, S.S.; VISHWAKARMA, R.A. Impact of preformulation on drug development. Expert Opin. Drugs Deliv. 2013, 10, 1239–1257
12. DARJI, M.A.; LALGE, R.M.; MARATHE, S.P.; MULAY, T.D.; FATIMA, T.; ALSHAMMARI, A.; LEE, H.K.; REPKA, M.A.; Narasimha Murthy, S. Excipient Stability in Oral Solid Dosage Forms: A Review. AAPS PharmSciTech 2018, 19, 12–26.
13. RAJAMMA, A. J., SATEESHA, S. B., NARODE, M. K., PRASHANTH, V. & KARTHIK, A. M. Preparation and
crystallographic analysis of gliclazide polymorphs. Indian J. Pharm. Sci. 77, 34 2015.
14. Brasil. Resolução RE n.º 897, de 29 de maio de 2003. Determina a publicação do Guia para isenção e substituição de estudos de bioequivalência. Diário Oficial da União, Seção 1. 2003 Jun 02. p. 54.
15. JONDHALE, S., BHISE, S. & PORE, Y. Physicochemical Investigations and Stability Studies of Amorphous Gliclazide. AAPS. Pharm.Sci. Tech. 13, 448–59 2012.
16. ALJOHANI, M., MCARDLE, P., ERXLEBEN, A., Dual-drug amorphous formulation of gliclazide. Drug development and Industrial Pharmacy 47, 302–307, 2021
17. ALCALÀ, M.; BLANCO, M.; BAUTISTA, M.; GONZÁLEZ, J.M. On-line monitoring of a granulation process by NIR spectroscopy. J. Pharm. Sci. 2010, 99, 336–345
18. ZABORENKO N., SHI Z., CORREDOR C.C., SMITHGOETTLER B.M., ZHANG L., HERMANS A., NEU C.M., ALAM M.A., COHEN M.J., LU X., et al. First-Principles and Empirical Approaches to Predicting In Vitro Dissolution for Pharmaceutical Formulation and Process Development and for Product Release Testing. AAPS J. 2019;21:1–20.
19. BOJARSKA, J.; REMKO, M.; BREZA, M.; MADURA, I.D.; KACZMAREK, K.; ZABROCKI, J.; WOLF, W.M. A Supramolecular Approach to Structure-Based Design with A Focus on Synthons Hierarchy in Ornithine-Derived Ligands: Review, Synthesis, Experimental and in Silico Studies. Molecules 2020, 25, 1135.
20. SPACKMAN M.A., JAYATILAKA D., Hirshfeld surface analysis, CrystEngComm. 11 2009 19–32.
21. MCKINNON J.J., MITCHELL, A.S., SPACKMAN, M.A., Visualising intermolecular interactions in crystals: naphthalene vs. terephthalic acid, Chemical Communications. 1998 2071– 2072.
22. MATTA, C. F., Modeling biophysical and biological properties from the characteristics of the molecular electron density, electron localization and delocalization matrices, and the electrostatic potential, Journal of Computational Chemistry. 35 2014 1165–1198.
23. ELANGOVAN, N, SOWRIRAJAN, S, Synthesis, single crystal (XRD), Hirshfeld surface analysis, computational study (DFT) and molecular docking studies of (E)-4-((2- hydroxy-3,5-diiodobenzylidene)amino)-N-(pyrimidine)-2-yl) benzenesulfonamide, Hellyon, 7 2021 e07724.
24. FRISCH, M. J. . et al. Gaussian 09, Revision A.02; Gaussian Inc.: Wallingford CT,. 2009
25. Brasil. Resolução-RDC n.º 37, de 3 de agosto de 2011. Dispõe sobre o Guia para isenção e substituição de estudos de biodisponibilidade relativa/bioequivalência e dá outras providências. Diário Oficial da União, Seção 1. 2011 Ago 5. p. 117-119.
26. THAKRAL S., THAKRAL N.K., MAJUMDAR D.K. Eudragit: A technology evaluation. Expert. Opin. Drug Deliv. 2013;10:131–149.
27. LOURENÇO V., LOCHMANN D., REICH G., MENEZES J.C., HERDLING T., SCHEWITZ J. A quality by design study applied to an industrial pharmaceutical fluid bed granulation. Eur. J. Pharm. Biopharam 2012
28. KWON H.J., HEO E.J., KIM Y.H., KIM S., HWANG Y.H., BYUN J.M. Development and evaluation of poorly water-soluble celecoxib as solid dispersions containing nonionic surfactants using fluidizedbed granulation. Pharmaceutics. 2019;11:136
29. FRANEK, F., JARLFORS, A., LARSEN, F., HOLM, P. &STEFFANSEN, B. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation. Eur J Pharm Sci 77, 303–313, 2015
30. MAPA, B. DE C., ARAÚJO, L. U., SILVA-BARCELLOS, N. M., CALDEIRA, T. G. & SOUZA, J. Gliclazide: Biopharmaceutics Characteristics to Discuss the Biowaiver of Immediate and Extended Release Tablets. Appl. Sci. 10, 7131 2020.
31. CHARALABIDIS A., SFOUNI M., BERGSTRÖM C., MACHERAS P. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines. Int. J. Pharm. 2019;566:264–281.
32. COUTINHO, W.F.; SILVA JÚNIOR, W.S. Diabetes care in Brazil. Ann. Glob. Health 2015, 81, 735–741.
33. DELEERS, M., GELBCKE, M., AND MALAISSE, W.J., Transport of Pr 3+ by hypoglycemic sulfonylureas across liposomal membranes. FEBS Lett. 151 1983 269272.
34. HOLMES B., HEEL R.C., BROGDEN R.N., SPEIGHT T.M., AVERY G.S., GLICLAZIDE A. A preliminary review of its pharmacodynamic properties and therapeutic efficacy diabetes mellitus. Drugs. 1984;27(4):301–327.
35. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality, Module 3, M4Q(R1), Sept. 2002.
36. QIAN C., Y. LIU, X. Chen, Improved synthesis of 1-[hexahydrocyclopenta[c]pyrrol-2 (1H)-yl]-3-(4- methylbenzenesulfonyl)urea, J. Chem. Res. 11 2008 635–636.
37. SPACKMAN, P.R.; YU, J.; MORTON, C.J.; PARKER, M.W.; BOND, C.S.; SPACKMAN, M.A.; JAYATILAKA, D.; THOMAS, S.P. Bridging crystal engineering and drug discovery bu ytilizing intermolceluar interactions and molecular shapes in crystals. Anghewandte 2019, 58, 16780–16784.
38. Tiţa B., Fuliaş A., Bandur G., Marian E., Tiţa D. Compatibility study between ketoprofen and pharmaceutical excipients used in solid dosage forms. J. Pharm. Biomed. 2011;56:221–227.
39. U.S. Department of Health and Human Services, Food and Drug Administration 2004 Guidance for industry: PAT—a framework for innovative pharmaceutical development, manufacturing, and quality assurance.
40. PALMER, K. J. & BROGDEN, R. N. Gliclazide. Drugs 46, 92–125 1993.
41. WU Y., DING Y., TANAKA Y., ZHANG W. 2014. Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention. Int. J. Med. Sci. 11 (11), 1185–1200. 10.7150/ijms.10001
